Related Experiment Video
Updated: Aug 18, 2026
Detection of Tissue-resident Bacteria in Bladder Biopsies by 16S rRNA Fluorescence In Situ Hybridization
Published on: October 18, 2019
Identification of a new prostate-specific cyclic peptide with the bacterial FliTrx system
Sabine Zitzmann1, Susanne Krämer, Walter Mier
1Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany. s.zitzmann@dkfz.de
Unlabelled:
Peptides are useful tools for directing radioisotopes into tumors. We evaluated the ability of a bacterial peptide display system to isolate new prostate tumor-specific peptides.
Methods:
We used the bacterial FliTrx system to identify a new cyclic peptide that binds to prostate carcinoma. Serum stability and binding affinities of the (125)I-labeled peptide were tested. Furthermore, the (131)I-labeled peptide was used to evaluate its biodistribution.
Results:
Several peptides showing a potential consensus motif were identified. The new peptide MM-2 is stable in serum for up to 24 h. It binds to PC-3 cells, and this binding can be inhibited more than 70% with the unlabeled peptide. Binding to human umbilical vein endothelial cells (HUVECs) and PNT-2 cells is weaker, and competition (27%) in HUVECs is less efficient. The biodistribution showed moderate accumulation in tumor.
Conclusion:
Bacterial peptide display, an alternative to phage peptide display, can allow the identification of specific binding and stable peptides.
